Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders

Aberrant expression ratio of Cl(−) transporters, NKCC1 and KCC2, is implicated in several brain conditions. NKCC1 inhibition by the FDA-approved diuretic drug, bumetanide, rescues core symptoms in rodent models and/or clinical trials with patients. However, bumetanide has a strong diuretic effect du...

Descripción completa

Detalles Bibliográficos
Autores principales: Savardi, Annalisa, Borgogno, Marco, Narducci, Roberto, La Sala, Giuseppina, Ortega, Jose Antonio, Summa, Maria, Armirotti, Andrea, Bertorelli, Rosalia, Contestabile, Andrea, De Vivo, Marco, Cancedda, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427514/
https://www.ncbi.nlm.nih.gov/pubmed/32818158
http://dx.doi.org/10.1016/j.chempr.2020.06.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427514/
https://www.ncbi.nlm.nih.gov/pubmed/32818158
http://dx.doi.org/10.1016/j.chempr.2020.06.017

Ejemplares similares